Results 121 to 130 of about 345,409 (245)

Approaches to repurposing reverse transcriptase antivirals in cancer

British Journal of Clinical Pharmacology, EarlyView.
This review highlights the role of reverse transcriptase (RT) inhibition in cellular regulation associated with non‐terminal repeat retrotransposons and endogenous retroviruses. Based on their pleiotropic characteristics, RT inhibitors (RTIs) are discussed as potential anticancer agents.
Richard Head, Saiful Islam, Jennifer H. Martin   +2 more
wiley   +1 more source

Mitochondria and Endoplasmic Reticulum Contact Site as a Regulator of Proteostatic Stress Responses in Neurodegenerative Diseases

BioEssays, EarlyView.
Recent findings indicate that mitochondria‐associated membranes (MAMs), where the endoplasmic reticulum directly contacts the mitochondria, are a novel microdomain essential for cellular homeostasis, including proteostasis. We summarize the disruption of protein homeostasis and MAM alteration in neurodegenerative diseases, then discuss challenges and ...
Seiji Watanabe, Koji Yamanaka
wiley   +1 more source

Compact Origins and Where to Find Them: ORC's Guide to Genome‐Wide Licensing

BioEssays, EarlyView.
Origin licensing is a key requirement for any eukaryotic cell to initiate DNA replication in S‐phase. Here, we review the most recent findings in the orchestrated action of the origin recognition complex (ORC) to sequentially load two MCM2‐7 helicases onto DNA with a focus on origin architecture and sequencing‐based methods.
Christian Speck, Luitpold Maximilian Reuter   +1 more
wiley   +1 more source

The contribution of extracellular RNA and its derived biomaterials in disease management

BMEMat, EarlyView.
The implications of exRNA's biological function and the structural uniqueness of RNA help establish a close connection between RNA, material, and modern medicine. Abstract The RNA found in the circular system is known as extracellular RNA (exRNA). This kind of RNA has been found to play a biological role similar to that of a messenger. They can be used
Yu Wei, Zhangyi Wang, Zixuan Qin, Qianqian Wan, Yutao Li, Franklin R. Tay, Chenyu Wang, Tong Zhang, Lina Niu   +8 more
wiley   +1 more source

Unveiling the complexity of cellular senescence in cancers: From mechanism to therapeutic opportunities

BMEMat, EarlyView.
This review highlights the complex roles of cellular senescence in cancer progression and suppression, discusses the mechanisms and regulatory pathways involved, and evaluates the efficacy of the “One‐Two punch” sequential treatment approach while addressing emerging challenges in this novel therapeutic strategy.
Qiuming Pan, Ye Zhu, Zhi Ye, Huayang Zhang, Junxi Wang, Guozhong Yi, Zhiyong Li, Rongyang Xu, Luyao Wang, Zhenzhen Wu, Songtao Qi, Guanglong Huang, Shanqiang Qu   +12 more
wiley   +1 more source

Mechanism of D-type cyclin recognition by the AMBRA1 E3 ligase receptor. [PDF]

Sci Adv
Wang Y, Liu M, Wang S, Mai X, Wang X, Teng F, Lyu T, Su MY, Stjepanovic G.   +8 more
europepmc   +1 more source

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu   +18 more
wiley   +1 more source

F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression. [PDF]

Nat Commun
Li F, Yu H, Zhang Y, Ma Y, Chen X, Zhang J, Sun L, Guo R, Wu Y, Zheng P, Wang X, Bie P, He F, Zhang L, Xie C, Xiong H.   +15 more
europepmc   +1 more source

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications, EarlyView.
Abstract Background The combined use of anti‐programmed cell death protein 1 (PD‐1)/anti‐cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and ...
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic, Sajeve S. Thomas, William R. Robinson III, Hye Sung Kim, Liam Il‐Young Chung, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock   +16 more
wiley   +1 more source

Niclosamide: CRL4^AMBRA1 mediated degradation of cyclin D1 following mitochondrial membrane depolarization. [PDF]

RSC Med Chem
Coomar S, Gasser JA, Słabicki M, Donovan KA, Fischer ES, Ebert BL, Gillingham D, Thomä NH.   +7 more
europepmc   +1 more source